-$0.15 EPS Expected for Histogenics Corp (HSGX) This Quarter

Share on StockTwits

Wall Street brokerages expect Histogenics Corp (NASDAQ:HSGX) to post earnings of ($0.15) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Histogenics’ earnings, with the lowest EPS estimate coming in at ($0.23) and the highest estimate coming in at ($0.11). Histogenics posted earnings per share of ($0.26) during the same quarter last year, which would indicate a positive year-over-year growth rate of 42.3%. The company is expected to announce its next earnings report on Thursday, March 21st.

According to Zacks, analysts expect that Histogenics will report full year earnings of ($0.46) per share for the current fiscal year, with EPS estimates ranging from ($0.54) to ($0.41). For the next financial year, analysts expect that the business will post earnings of ($0.46) per share, with EPS estimates ranging from ($0.78) to ($0.21). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Histogenics.

Histogenics (NASDAQ:HSGX) last released its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.05).

HSGX has been the topic of several research reports. BTIG Research downgraded shares of Histogenics from a “buy” rating to a “neutral” rating and set a $3.50 price objective on the stock. in a report on Wednesday, September 5th. Needham & Company LLC increased their price target on shares of Histogenics to $5.00 and gave the company a “buy” rating in a research report on Thursday, September 6th. HC Wainwright restated a “buy” rating and set a $2.00 price target on shares of Histogenics in a research report on Wednesday, September 5th. Zacks Investment Research lowered shares of Histogenics from a “hold” rating to a “sell” rating in a research report on Thursday, October 11th. Finally, Brookline Cap M restated a “buy” rating on shares of Histogenics in a research report on Wednesday, August 1st. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Histogenics currently has a consensus rating of “Buy” and an average target price of $3.25.

HSGX opened at $0.44 on Tuesday. Histogenics has a 1-year low of $0.37 and a 1-year high of $3.35. The firm has a market cap of $12.86 million, a price-to-earnings ratio of -0.45 and a beta of 1.02.

A number of large investors have recently modified their holdings of the business. Renaissance Technologies LLC boosted its position in Histogenics by 6.1% during the second quarter. Renaissance Technologies LLC now owns 384,329 shares of the biotechnology company’s stock worth $961,000 after purchasing an additional 22,133 shares during the period. BlackRock Inc. boosted its position in Histogenics by 72.0% during the second quarter. BlackRock Inc. now owns 54,753 shares of the biotechnology company’s stock worth $137,000 after purchasing an additional 22,927 shares during the period. DRW Securities LLC bought a new position in Histogenics during the second quarter worth about $242,000. JPMorgan Chase & Co. bought a new position in Histogenics during the first quarter worth about $320,000. Finally, Virtu Financial LLC bought a new position in Histogenics during the third quarter worth about $117,000. Hedge funds and other institutional investors own 45.68% of the company’s stock.

About Histogenics

Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

Recommended Story: What is a capital gain?

Get a free copy of the Zacks research report on Histogenics (HSGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply